Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Invested Capital (2016 - 2025)

Marker Therapeutics has reported Invested Capital over the past 12 years, most recently at $16.8 million for Q4 2025.

  • Quarterly Invested Capital fell 9.49% to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Dec 2025, down 9.49% year-over-year, with the annual reading at $16.8 million for FY2025, 9.49% down from the prior year.
  • Invested Capital was $16.8 million for Q4 2025 at Marker Therapeutics, down from $18.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $72.5 million in Q1 2021 and troughed at $7.4 million in Q3 2024.
  • The 5-year median for Invested Capital is $18.5 million (2024), against an average of $26.3 million.
  • Year-over-year, Invested Capital crashed 55.43% in 2023 and then soared 146.84% in 2025.
  • A 5-year view of Invested Capital shows it stood at $44.0 million in 2021, then crashed by 49.75% to $22.1 million in 2022, then tumbled by 36.42% to $14.1 million in 2023, then surged by 32.06% to $18.6 million in 2024, then decreased by 9.49% to $16.8 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Invested Capital are $16.8 million (Q4 2025), $18.4 million (Q3 2025), and $10.5 million (Q2 2025).